H.C. Wainwright Maintains Positive Ratings for Three Biotech Stocks

H.C. Wainwright has reaffirmed its investment ratings for Immuneering, Gossamer Bio, and Voyager Therapeutics, citing promising developments in their respective drug pipelines. The analysts highlighted advancing clinical trials and regulatory milestones as key drivers for future valuation.